Clinical trial
A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
NCT00085969 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
- Lead sponsor
- AstraZeneca
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2003
- Completion date
- January 31, 2004
- Enrollment
- 99 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.